IRCT20200413047062N1已完成3 期
Evaluating the efficacy of Atorvastatin in clinical improvement, prognosis and hospitalization course in patients with COVID-19 infection
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 76
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Patients age over 18 years
- •Hospitalized with diagnosis of COVID-19 infection
排除标准
- •History of hypersensitivity reaction to atorvastatin,
- •Liver dysfunction (Liver enzymes > 3 ULN or bilirubin >2 ULN or history of liver failure)
- •Renal failure (eGFR < 30ml/min),
- •History of major side effects with statins (such as liver toxicity, rhabdomyolysis)
- •Patients are receiving other drugs which have major interaction (such as Gemfibrozil, cyclosporine, amiodarone, itraconazole, variconazole, clarithromycin)
- •LDL Level below than 40 mg/dl
- •Involvement in another clinical study
研究者
相似试验
已完成
3 期
A study to evaluate the effect of Atorvastatin in GvHDCondition 1: Acute lymphoblastic leukemia [ALL]. Condition 2: Acute myeloid leukemia [AML].Acute myeloblastic leukemiac91.0C92.0IRCT20140818018842N27Tehran University of Medical Sciences75
招募中
3 期
Effect of Atorvastatin in the management of COVID-19COVID-19.Coronavirus infection, unspecifiedB34.2IRCT20150221021159N7Esfahan University of Medical Sciences60
已完成
2 期
Atorvastatin effect on COVID-19IRCT20190727044343N2Mazandaran University of Medical Sceinces100
已完成
不适用
Clinical research of atorvastatin to evaluate the effect of OATP2B1 inhibition and drug-drug interactiohealthy male and femaleJPRN-UMIN000009480Department of clinical pharmacokinetics, Kyushu University24
已完成
不适用
Clinical research of atorvastatin to evaluate the effect of OATP2B1 inhibitioJPRN-UMIN000005864Department of clinical pharmacokinetics, Kyushu University16